Trevi Therapeutics
Trevi Therapeutics
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07868419 | |
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT07671911 | |
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | Chronic Cough, Cough, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Signs and Symptoms, Respiratory, respiratory system disorder | Recruiting | Phase 2 | 2026-08-10 | NCT07671924 |